The malaria drug is quickly falling out of favor with the medical community as a potential treatment for the disease. On the back of mounting concerns about hydroxychloroquine's safety, global pharmaceutical major Sanofi (NASDAQ:SNY) has quit providing it to COVID-19 patients enrolled in its clinical trials for the drug. It has also put a temporary…
A box of Plaquenil, an anti-malaria drug hydroxychloroquine made by Sanofi, used for years to treat malaria and autoimmune disorders.Alain Pitton | NurPhoto | Getty ImagesFrench drugmaker Sanofi said Friday it is suspending recruitment of new patients for its clinical trials looking at anti-malaria drug hydroxychloroquine as a potential treatment for the coronavirus.The company is also…
In an interview, Sanofi (NASDAQ:SNY) chief Paul Hudson said the company can produce up to 600M doses of its coronavirus vaccine next year if studies with partner GlaxoSmithKline (NYSE:GSK) proceed as planned. Clinical trials should launch in H2 with product availability about a year later if all goes well. "We believe that we're one of…
U.S.|Grand Juror in Breonna Taylor Case Says Deliberations Were MisrepresentedThe Kentucky attorney general’s office said it would release the panel’s recordings after a grand juror contended in a court filing that its discussions were inaccurately characterized.Breonna Taylor's family and the lawyer Ben Crump, right, said the charges a Kentucky grand jury agreed upon in the…
(John Finney Photography/Moment/Getty Images) An abnormally bad season of weather may have had a significant impact on the death toll from both World War I and the 1918 Spanish flu pandemic, according to new research, with many more lives being lost due to torrential rain and plummeting temperatures. Through a detailed analysis of an ice…